跳至主要内容
临床试验/NCT00005666
NCT00005666已完成不适用

Utility of Anatometabolic Imaging for Radiation Treatment Planning for Lung Cancer

National Center for Research Resources (NCRR)2 个研究点 分布在 1 个国家开始时间: 2000年5月22日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
试验地点
2

研究概览

简要总结

This is a research study for patients with inoperable lung cancer called non-small cell lung cancer (NSCLC). Currently, the information from a radiological test, computed tomography (CT) scan of the chest, is used to design the best arrangement of radiation beams which will kill tumor cells and still spare the normal parts of lungs and other normal organs in the chest. The purpose of this study is to explore whether adding information from another radiological test, called positron emission tomography (PET), will improve the accuracy of the radiation beam arrangement designed to treat lung cancer. A PET scan is a way to picture the biochemistry of tissues and organs: of how tissues in the body take up glucose, a normal nutrient of the body. The researchers will attempt to create radiation treatment plans from PET images alone and compare differences between hypothetical plans and standard-of-care CT-based radiation treatment plans. Because there is honest uncertainty about the contribution of PET to radiation treatment planning, it is possible that there will be no difference between a CT-based treatment plan and one resulting from PET information. It is also possible that the addition of PET may result in a radiation beam arrangement that may better control lung cancer. The addition of PET may also result in treating less normal tissues, which may lower the risk of radiation side effects. This study will provide the preliminary data necessary to design a larger clinical trial that may define the role of PET in radiation treatment planning.

研究设计

研究类型
Interventional
主要目的
Treatment
盲法
None

入排标准

年龄范围
0 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Histologically confirmed locally advanced NSCLC (squamous, large cell undifferentiated or adenocarcinoma).
  • Disease limited to the thorax, adjacent mediastinum and neurovascular structures, and supraclavicular or scalene lymph node area, as defined by the AJCC Staging System. This includes patients with Stage IIIA and IIIB disease.
  • Performance status of 0-2 by Southwest Oncology Group criteria.
  • Medically inoperable patients (Stage I or II)
  • Locoregional recurrent tumor following surgery will be eligible provided they meet other eligibility criteria.

排除标准

  • 未提供

研究者

发起方
National Center for Research Resources (NCRR)
申办方类型
Nih

研究点 (2)

Loading locations...

相似试验